About Kineta

Kineta is a clinical-stage biotechnology company with a mission to develop next-generation cancer immunotherapies that may transform patients’ lives. The company has leveraged expertise in innate immunity to advance a focused pipeline of novel immuno-oncology drugs. There is significant commercial potential for Kineta’s assets as the global market for immuno-oncology therapies is forecast to grow to $95 billion by 2026. Kineta announced the reverse merger with NASDAQ-listed Yumanity Therapeutics (YMTX) on June 6, 2022, providing a clear path to a public market liquidity event for investors.